4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (FDMT)

CUSIP: 35104E100

Q3 2023 13F Holders as of 30 Sep 2023

Holder snapshot 7 signals
Share change
+654,278
Put/Call ratio
97%
SEC-reported price per share
$12.73
Number of holders
110
Value change
+$5,221,810
Number of buys
61
Open additional details 1 more signal available
Number of sells
43
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
51,571,939

Security key

35104E100

Report period

Q3 2023

Institutions

110

Top holders

10

Ownership snapshot

Top reported holders of FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
0/15
Latest evidence
30 Jun 2023
13F 3/4/5 Highest disclosed value: $86,517,606 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

VIKING GLOBAL INVESTORS LP has the largest disclosed position value at $86.52M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Disclosed position value Top 5
VIKING GLOBAL INVESTORS LP $86.52M
BVF INC/IL $72.41M
RA CAPITAL MANAGEMENT, L.P. $55.47M
Venrock Adviser, LLC $54.21M
BlackRock Finance, Inc. $52.66M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VIKING GLOBAL INVESTORS LP
13F
Company
13F
—
denominator unverified
$86,517,606
4,787,914 shares
— 30 Jun 2023
BVF INC/IL
13F
Company
13F
—
denominator unverified
$72,413,953
4,007,413 shares
— 30 Jun 2023
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$55,466,425
3,069,531 shares
— 30 Jun 2023
Venrock Adviser, LLC
13F
Company
13F
—
denominator unverified
$54,210,000
3,000,000 shares
— 30 Jun 2023
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$52,663,750
2,914,430 shares
— 30 Jun 2023
Janus Henderson Group Ltd.
13F
Company
13F
—
denominator unverified
$51,276,601
2,838,882 shares
— 30 Jun 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
110
Shares
41,913,779
Rows available
110
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders
100
Q3 2023 holders
110
Holder diff
10
Investor Q2 2023 Shares Q3 2023 Shares Share Diff Share Chg % Q2 2023 value Q3 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .